Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Official title

The Phase III 'High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer

Overview

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.

Detailed description

PRIMARY OBJECTIVE:

I. To compare metastasis-free survival, determined using conventional imaging, between men with high-risk prostate cancer randomized to ultrahypofractionation (stereotactic body radiation therapy \[SBRT\]) to those randomized to moderate hypofractionation and conventional fractionation.

SECONDARY OBJECTIVES:

I. To compare physician-reported toxicity as measured by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5 between treatment arms.

II. To determine if ultrahypofractionation is non-inferior to moderate hypofractionation and conventional fractionation with respect to patient-reported urinary function (assessed by Expanded Prostate Cancer Index Composite \[EPIC\]-26 urinary domains).

III. To determine if ultrahypofractionation is non-inferior to moderate hypofractionation and conventional fractionation with respect to patient-reported bowel function (assessed by EPIC-26 bowel domain).

IV. To compare patient-reported fatigue (assessed by Patient Reported Outcomes Measurement Information System \[PROMIS\]-Fatigue) between treatment arms.

V. To compare failure-free survival between treatment arms. VI. To compare metastasis-free survival based on molecular imaging between treatment arms.

VII. To compare overall survival between treatment arms.

EXPLORATORY OBJECTIVES:

I. To compare patient-reported sexual function (assessed by EPIC-26 sexual domain) between treatment arms.

II. To compare patient-reported quality of life (assessed by European Quality of Life Five Dimension Five Level Scale Questionnaire \[EQ-5D-5L\]) between treatment arms.

III. To compare patient-reported treatment burden (assessed by COmprehensive Score for financial Toxicity (COST)) between treatment arms

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients undergo SBRT for a total of 5 treatments over 2 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo bone scan and/or computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)/CT during screening and CT and/or MRI on study. Additionally, patients may optionally undergo blood and urine sample collection on study.

ARM II: Patients undergo external beam radiation treatment (EBRT) for 20-45 treatments over 4 to 9 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo bone scan and/or CT, MRI, or PET/CT during screening and CT and/or MRI on study. Additionally, patients may optionally undergo blood and urine sample collection on study.

Patients are followed up every 6 months for 5 years.

Interventions

• Procedure Biospecimen Collection
  Undergo blood and urine sample collection
• Procedure Bone Scan
  Undergo bone scan
• Procedure Computed Tomography
  Undergo CT or PET/CT
• Radiation External Beam Radiation Therapy
  Undergo EBRT
• Procedure Magnetic Resonance Imaging
  Undergo MRI
• Procedure Positron Emission Tomography
  Undergo PET/CT
• Other Quality-of-Life Assessment
  Ancillary studies
• Other Questionnaire Administration
  Ancillary studies
• Radiation Stereotactic Body Radiation Therapy
  Undergo SBRT

Primary outcome measures

• Metastasis-free survival (MFS) [Time frame: From randomization to the date of distant metastasis, or death from any cause, assessed up to 15 years]

Secondary outcome measures (8)

• Failure-free survival [Time frame: From randomization to the date of distant metastasis, or death from any cause, assessed up to 15 years]
• Overall survival [Time frame: From the date of randomization to the date of death or last known follow-up date, with patients alive at the last known follow-up time treated as censored, assessed up to 15 years]
• MFS [Time frame: From randomization to the date of distant metastasis, or death from any cause, assessed up to 15 years]
• Incidence of adverse events (AEs) [Time frame: Up to 15 years]
• Urinary incontinence [Time frame: Up to 5 years]
• Urinary irritative/obstructive [Time frame: Up to 5 years]
• Bowel function [Time frame: Up to 5 years]
• Fatigue [Time frame: Up to 5 years]

Eligibility criteria

Inclusion criteria

• Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of prostate cancer
• High-risk disease defined as having at least one or more of the following:

• cT3a-T3b by digital exam or imaging (American Joint Committee on Cancer \[AJCC\] 8th edition \[Ed.\]) Note: cT4 by imaging or on digital rectal exam is not allowed
• The patient's prostate specific antigen (PSA) value > 20 ng/mL prior to starting androgen deprivation therapy (ADT) Note: Patients taking a 5-alpha reductase inhibitor (ex finasteride or dutasteride) are eligible The baseline PSA value should be doubled for PSAs taken while on 5-alpha reductase inhibitors
• Gleason Score of 8-10
• Pelvic node positive by conventional imaging with a short axis of at least 1.0 cm
• Prostate gland volume less than 100 cc prior to initiation of ADT as reported at time of biopsy or by separate measure with ultrasound or other imaging modalities including MRI or CT scan
• No definitive clinical or radiologic evidence of metastatic disease outside of the pelvic nodes (M1a, M1b or M1c) on conventional imaging (i.e. bone scan, CT scan, MRI); Negative prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is an acceptable substitute
• Age >= 18
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
• No prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
• No prior radical prostatectomy
• No prior ablative or focal therapy to the prostate (including, but not limited to, transrectal or transurethral high-intensity focused ultrasound \[HIFU\], laser ablation, cryotherapy, irreversible electroporation \[IRE\], and vascular-targeted photodynamic therapy)
• Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both luteinizing hormone releasing hormone \[LHRH\] agonist and oral anti-androgen) is =< 185 days prior to registration; Please note: PSA prior to the start of any ADT will be used to define disease
• No contraindication to prostate MRI (required for planning of radiotherapy in both arms)
• Patients enrolled in NRG-GU009 must be enrolled in NRG-GU013 prior to radiation therapy treatment planning and start of radiation therapy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 402 centers

• University of Alabama at Birmingham Cancer Center — Birmingham
• The Kirklin Clinic at Acton Road — Birmingham
• Lewis and Faye Manderson Cancer Center — Tuscaloosa
• University of Arkansas for Medical Sciences — Little Rock
• Kaiser Permanente-Deer Valley Medical Center — Antioch
• Tower Cancer Research Foundation — Beverly Hills
• Kaiser Permanente Dublin — Dublin
• Kaiser Permanente-Fremont — Fremont
• … and 394 more centers

Canada · 9 centers

Center list to be confirmed — check the primary protocol.

Hong Kong · 1 center

Center list to be confirmed — check the primary protocol.

Switzerland · 1 center

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT05946213 · NRG-GU013 · NCI-2023-04142 · NRG-GU013 · NRG-GU013 · U10CA180868

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗